Early👀9-29-26
Spu+14, Naz+110, DJI+95
10-yr 5.21$, JP40Y 4.23%
Crude-1,5%, Gold+.35%, Slv-.8%
BTC+.9%
RATING CHANGES
UP: BLMN, MAIN, NFLX, RZLT, SFTX, STAA, TCPC
DN: ABR, CGBD, FME, FSK, LFCR, MNDY, PEP, R,
WBD
Spu+14, Naz+110, DJI+95
10-yr 5.21$, JP40Y 4.23%
Crude-1,5%, Gold+.35%, Slv-.8%
BTC+.9%
RATING CHANGES
UP: BLMN, MAIN, NFLX, RZLT, SFTX, STAA, TCPC
DN: ABR, CGBD, FME, FSK, LFCR, MNDY, PEP, R,
WBD
September 29, 2026 at 12:34 PM
Early👀9-29-26
Spu+14, Naz+110, DJI+95
10-yr 5.21$, JP40Y 4.23%
Crude-1,5%, Gold+.35%, Slv-.8%
BTC+.9%
RATING CHANGES
UP: BLMN, MAIN, NFLX, RZLT, SFTX, STAA, TCPC
DN: ABR, CGBD, FME, FSK, LFCR, MNDY, PEP, R,
WBD
Spu+14, Naz+110, DJI+95
10-yr 5.21$, JP40Y 4.23%
Crude-1,5%, Gold+.35%, Slv-.8%
BTC+.9%
RATING CHANGES
UP: BLMN, MAIN, NFLX, RZLT, SFTX, STAA, TCPC
DN: ABR, CGBD, FME, FSK, LFCR, MNDY, PEP, R,
WBD
BioPharmCatalyst Watchlist: Top Phase 3 biotech catalysts for the next 6 months. Key tickers: XENE, OCGN, IRON, RNAC, DNTH, LXRX, HELP, RZLT, PCVX, MANE. More: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/se...
September 25, 2026 at 8:15 PM
BioPharmCatalyst Watchlist: Top Phase 3 biotech catalysts for the next 6 months. Key tickers: XENE, OCGN, IRON, RNAC, DNTH, LXRX, HELP, RZLT, PCVX, MANE. More: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/se...
🚨 $RZLT
On September 24, 2026, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit ...
On September 24, 2026, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit ...
SEC Filing: RZLT
Click to view the official SEC document.
www.sec.gov
September 24, 2026 at 8:27 PM
🚨 $RZLT
On September 24, 2026, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit ...
On September 24, 2026, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit ...
#RZLT Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/RZLT/rezolute-reports-fourth-quarter-and-full-year-fiscal-2026-financial-5opg3xakvbzs.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RZLT/rezolute-reports-fourth-quarter-and-full-year-fiscal-2026-financial-5opg3xakvbzs.html?utm_source=stocktitan-bluesky&utm_medium=social
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 24, 2026 at 8:05 PM
#RZLT Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/RZLT/rezolute-reports-fourth-quarter-and-full-year-fiscal-2026-financial-5opg3xakvbzs.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RZLT/rezolute-reports-fourth-quarter-and-full-year-fiscal-2026-financial-5opg3xakvbzs.html?utm_source=stocktitan-bluesky&utm_medium=social
#RZLT Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
https://www.stocktitan.net/news/RZLT/rezolute-provides-update-on-fda-review-of-its-phase-3-sun-rize-study-9bfil1upkb1l.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RZLT/rezolute-provides-update-on-fda-review-of-its-phase-3-sun-rize-study-9bfil1upkb1l.html?utm_source=stocktitan-bluesky&utm_medium=social
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 9, 2026 at 11:00 AM
#RZLT Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
https://www.stocktitan.net/news/RZLT/rezolute-provides-update-on-fda-review-of-its-phase-3-sun-rize-study-9bfil1upkb1l.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RZLT/rezolute-provides-update-on-fda-review-of-its-phase-3-sun-rize-study-9bfil1upkb1l.html?utm_source=stocktitan-bluesky&utm_medium=social
An “undue” burden: Nuns and golf course among 30-plus to appeal RZLT
https://www.fogolf.com/1372392/an-undue-burden-nuns-and-golf-course-among-30-plus-to-appeal-rzlt/
Nuns on the run from a potential tax bill. A local authority adding its own property…
https://www.fogolf.com/1372392/an-undue-burden-nuns-and-golf-course-among-30-plus-to-appeal-rzlt/
Nuns on the run from a potential tax bill. A local authority adding its own property…
An "undue" burden: Nuns and golf course among 30-plus to appeal RZLT - FOGOLF | FOLLOW GOLF | FOGOLF.COM
Nuns on the run from a potential tax bill. A local authority adding its own property arm to its tax map. A private golf course facing up to an “undue
www.fogolf.com
August 31, 2026 at 6:40 AM
An “undue” burden: Nuns and golf course among 30-plus to appeal RZLT
https://www.fogolf.com/1372392/an-undue-burden-nuns-and-golf-course-among-30-plus-to-appeal-rzlt/
Nuns on the run from a potential tax bill. A local authority adding its own property…
https://www.fogolf.com/1372392/an-undue-burden-nuns-and-golf-course-among-30-plus-to-appeal-rzlt/
Nuns on the run from a potential tax bill. A local authority adding its own property…
$HAS-1 $BULL-1 $PL-1 $OPTX-1 $AMZU-1 $OPEN-1 $BEX-1 $CRK-1 $SSPC-1 $SOXX-1 $TSLL-1 $LOW-1 $BKNG-1 $SFNC-1 $CGNT-1 $AAOX-1 $NUAI-1 $IHI-1 $MSFT-1 $SPYG-1 $RZLT-1 $JNJ-1 $RRC-1 $CCL-1 $NXE-1 $SE-1 $C-1 $EBAY-1 $MSTX-1 $KRNY-1 $SGHC-1 $EXC-1 $DFNS-1 $ULCC-1
July 28, 2026 at 8:48 PM
$HAS-1 $BULL-1 $PL-1 $OPTX-1 $AMZU-1 $OPEN-1 $BEX-1 $CRK-1 $SSPC-1 $SOXX-1 $TSLL-1 $LOW-1 $BKNG-1 $SFNC-1 $CGNT-1 $AAOX-1 $NUAI-1 $IHI-1 $MSFT-1 $SPYG-1 $RZLT-1 $JNJ-1 $RRC-1 $CCL-1 $NXE-1 $SE-1 $C-1 $EBAY-1 $MSTX-1 $KRNY-1 $SGHC-1 $EXC-1 $DFNS-1 $ULCC-1
Dan McSweeney asks if the council will be liable for the upcoming Administered by Revenue because Councils Have Been Shit At It derelict properties tax.
No official answer yet, but probably yes, like the RZLT (the residential zoned land tax: it's 3% pa)
That's gonna be funny. And expensive.
No official answer yet, but probably yes, like the RZLT (the residential zoned land tax: it's 3% pa)
That's gonna be funny. And expensive.
July 13, 2026 at 3:55 PM
Dan McSweeney asks if the council will be liable for the upcoming Administered by Revenue because Councils Have Been Shit At It derelict properties tax.
No official answer yet, but probably yes, like the RZLT (the residential zoned land tax: it's 3% pa)
That's gonna be funny. And expensive.
No official answer yet, but probably yes, like the RZLT (the residential zoned land tax: it's 3% pa)
That's gonna be funny. And expensive.
Tori Amos - Girl - Orlando, FL - 7/9/26 www.youtube.com/watch?v=RzLT...
Tori Amos - Girl - Orlando, FL - 7/9/26
YouTube video by Spinny78
www.youtube.com
July 10, 2026 at 12:05 PM
Tori Amos - Girl - Orlando, FL - 7/9/26 www.youtube.com/watch?v=RzLT...
🚨 $RZLT
ROBERTS BRIAN KENNETH (Chief Medical Officer) reported special transactions (Non-P/S).
ROBERTS BRIAN KENNETH (Chief Medical Officer) reported special transactions (Non-P/S).
SEC Filing: RZLT
Click to view the official SEC document.
www.sec.gov
July 7, 2026 at 10:36 PM
🚨 $RZLT
ROBERTS BRIAN KENNETH (Chief Medical Officer) reported special transactions (Non-P/S).
ROBERTS BRIAN KENNETH (Chief Medical Officer) reported special transactions (Non-P/S).
🚨 $RZLT
Elam Nevan C (CEO) reported special transactions (Non-P/S).
Elam Nevan C (CEO) reported special transactions (Non-P/S).
SEC Filing: RZLT
Click to view the official SEC document.
www.sec.gov
July 7, 2026 at 9:28 PM
🚨 $RZLT
Elam Nevan C (CEO) reported special transactions (Non-P/S).
Elam Nevan C (CEO) reported special transactions (Non-P/S).
🚨 $RZLT
Evans Daron (CFO) reported special transactions (Non-P/S).
Evans Daron (CFO) reported special transactions (Non-P/S).
SEC Filing: RZLT
Click to view the official SEC document.
www.sec.gov
July 7, 2026 at 9:26 PM
🚨 $RZLT
Evans Daron (CFO) reported special transactions (Non-P/S).
Evans Daron (CFO) reported special transactions (Non-P/S).
Small-cap stocks in new uptrend according to average directional index, Thu Jun 4th - #$NEXT #$MSS #$MIRA #$ZJYL #$VERU #$SPRO #$RZLT #$QRHC #$PRGS #$PDFS #$NUTX #$MOMO #$LFCR #$FRST #$ELBM #$ECX #$BNGO #$APPN #$WMK #$GPRK - More: crystalequityresearch.com/leading-indi... - #smallcap
Leading Indicators, Thursday June 4, 2026 – Crystal Equity Research
crystalequityresearch.com
June 4, 2026 at 9:24 PM
#RZLT Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
https://www.stocktitan.net/news/RZLT/rezolute-announces-four-presentations-at-the-upcoming-annual-meeting-77o0x7k03ua1.html
https://www.stocktitan.net/news/RZLT/rezolute-announces-four-presentations-at-the-upcoming-annual-meeting-77o0x7k03ua1.html
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Rezolute (Nasdaq:RZLT) will deliver four presentations at the Endocrine Society’s ENDO 2026 meeting in Chicago from June 13-16, 2026.The schedule includes an oral presentation of Phase 3 sunRIZE top-line results for congenital hyperinsulinism and three posters covering congenital and tumor hyperinsulinism outcomes and ersodetug (RZ358) clinical experience.
www.stocktitan.net
June 4, 2026 at 11:30 AM
#RZLT Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
https://www.stocktitan.net/news/RZLT/rezolute-announces-four-presentations-at-the-upcoming-annual-meeting-77o0x7k03ua1.html
https://www.stocktitan.net/news/RZLT/rezolute-announces-four-presentations-at-the-upcoming-annual-meeting-77o0x7k03ua1.html
Rezolute announces Phase 3 sunRIZE study results via oral presentation
$RZLT 8-K → https://filingdiff.com/ticker/RZLT/0001104659-26-054943/
$RZLT 8-K → https://filingdiff.com/ticker/RZLT/0001104659-26-054943/
June 3, 2026 at 5:40 PM
Rezolute announces Phase 3 sunRIZE study results via oral presentation
$RZLT 8-K → https://filingdiff.com/ticker/RZLT/0001104659-26-054943/
$RZLT 8-K → https://filingdiff.com/ticker/RZLT/0001104659-26-054943/
$CNTB director James Huang bought 150K shares for $370.5K, signaling insider confidence. $CNTB $A $NRXP $MLYS $AIM $RZLT $RNAZ $ABVX $SNGX $BJDX
www.biopharmcatalyst.com/news/2026/nr...
www.biopharmcatalyst.com/news/2026/nr...
Pre-Market Updates 06/03/26
export-download.canva.com
June 3, 2026 at 12:40 PM
$CNTB director James Huang bought 150K shares for $370.5K, signaling insider confidence. $CNTB $A $NRXP $MLYS $AIM $RZLT $RNAZ $ABVX $SNGX $BJDX
www.biopharmcatalyst.com/news/2026/nr...
www.biopharmcatalyst.com/news/2026/nr...
#$RZLT drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish. notreload.xyz/xy/rezolute-...
Rezolute (RZLT) Upgraded by Analysts on Strong Phase 3 Data
Rezolute’s drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish.
notreload.xyz
June 3, 2026 at 10:49 AM
#$RZLT drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish. notreload.xyz/xy/rezolute-...
🟢 #$RZLT — Clinical Readout
Phase 3 upLIFT Positive Interim Data - 6 of 8 Participants Met Primary Endpoint
Rezolute announced positive interim data from the Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. Of 8 enrolled participants (study is 50% en…
https://biostock.app/symbols/RZLT
Phase 3 upLIFT Positive Interim Data - 6 of 8 Participants Met Primary Endpoint
Rezolute announced positive interim data from the Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. Of 8 enrolled participants (study is 50% en…
https://biostock.app/symbols/RZLT
June 2, 2026 at 3:37 PM
🟢 #$RZLT — Clinical Readout
Phase 3 upLIFT Positive Interim Data - 6 of 8 Participants Met Primary Endpoint
Rezolute announced positive interim data from the Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. Of 8 enrolled participants (study is 50% en…
https://biostock.app/symbols/RZLT
Phase 3 upLIFT Positive Interim Data - 6 of 8 Participants Met Primary Endpoint
Rezolute announced positive interim data from the Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. Of 8 enrolled participants (study is 50% en…
https://biostock.app/symbols/RZLT
$RZLT · Material event
Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint
#SEC #stocks #investing #RZLT
🔗 secwatch.observer
Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint
#SEC #stocks #investing #RZLT
🔗 secwatch.observer
June 2, 2026 at 12:03 PM
$RZLT · Material event
Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint
#SEC #stocks #investing #RZLT
🔗 secwatch.observer
Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint
#SEC #stocks #investing #RZLT
🔗 secwatch.observer
🚨 $RZLT
On June 2, 2026, Rezolute, Inc. issued a press release to announce an interim update on its upLIFT study.
On June 2, 2026, Rezolute, Inc. issued a press release to announce an interim update on its upLIFT study.
SEC Filing: RZLT
Click to view the official SEC document.
www.sec.gov
June 2, 2026 at 11:11 AM
🚨 $RZLT
On June 2, 2026, Rezolute, Inc. issued a press release to announce an interim update on its upLIFT study.
On June 2, 2026, Rezolute, Inc. issued a press release to announce an interim update on its upLIFT study.
#RZLT Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
https://www.stocktitan.net/news/RZLT/rezolute-announces-positive-interim-data-for-its-phase-3-up-lift-sx2vf695cp7j.html
https://www.stocktitan.net/news/RZLT/rezolute-announces-positive-interim-data-for-its-phase-3-up-lift-sx2vf695cp7j.html
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute (Nasdaq:RZLT) reported positive interim data from its open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. The trial is 50% enrolled, with 8 of 16 planned participants.According to Rezolute, 6 of 8 participants met the primary endpoint responder criterion and fully discontinued intravenous glucose. Ersodetug has been well-tolerated with no drug-related adverse events reported. Topline results are expected in the second half of 2026.
www.stocktitan.net
June 2, 2026 at 11:00 AM
#RZLT Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
https://www.stocktitan.net/news/RZLT/rezolute-announces-positive-interim-data-for-its-phase-3-up-lift-sx2vf695cp7j.html
https://www.stocktitan.net/news/RZLT/rezolute-announces-positive-interim-data-for-its-phase-3-up-lift-sx2vf695cp7j.html
🚨 $RZLT
8-K Analysis Error: list index out of range
8-K Analysis Error: list index out of range
SEC Filing: RZLT
Click to view the official SEC document.
www.sec.gov
May 12, 2026 at 8:42 PM
🚨 $RZLT
8-K Analysis Error: list index out of range
8-K Analysis Error: list index out of range